Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 18 of 18 for “"neratinib"”.
-
An Investigation of Biological Processes Underlying Neratinib-induced Gut Injury
Neratinib, a small-molecule tyrosine kinase inhibitor (TKI) that irreversibly binds to human epidermal growth factor receptors 1,2, and 4 (HER1, 2 and 4), was recently approved as an adjuvant therapy for patients with HER2-amplified or -overexpressed (HER2-positive) breast cancer. However, in …
-
Pre-clinical rationale for new indications and novel combinations of the tyrosine kinase inhibitor neratinib in cancer
… to investigate the efficacy of the pan-HER TKI neratinib in HER-driven cancers outside of BC and to develop therapeutic strategies to treat those cancers and overcome potential resistance. Methods: The efficacy of neratinib alone and combinations of neratinib with inhibitors like dasatinib …
-
Role of Drug Metabolizing Enzymes in Cancer Drug Gastrointestinal Toxicity
… mange drug metabolism-associated GI side effect. Neratinib, a breast cancer targeted therapy mainly metabolized by cytochrome P450 (CYP)3A enzyme, draws worldwide concerns due to its extraordinarily high-incident diarrhea. The phase III trial of neratinib showed that 96% of the patients taking …
-
Assessing the effects of anti-HER2 treatments in combination with hormone treatment and immunotherapy in HER2-Low breast cancer
… such as tyrosine kinase inhibitors like neratinib. Therefore, my PhD project aims to investigate the effects of different anti-HER2 treatments (trastuzumab) or their combination with hormone treatments or immunotherapy in HER2-low-expressing breast cancer (BC) cells and patient-derived …
-
Role of HER-targeted tyrosine kinase inhibitors in the treatment of high grade serous ovarian cancer
… of five TKIs (afatinib, canertinib, lapatinib, neratinib and sapitinib) targeted against multiple HER family members on cellular functionality were studied in three pairs of HGSOC cell lines, wherein each pair was derived from the same patient before and after clinical resistance to …
-
Targeting neutrophil cell death as a treatment for multimorbidity
… work indicates that the EGFR/ErbB inhibitor, neratinib, induces neutrophil apoptosis and increases efferocytosis rates in macrophages in vivo. Moreover, the PKCβII inhibitor ruboxistaurin has previously been shown to inhibit NET formation. This study presents findings in support of the ideas …
-
Investigating combinations of tyrosine kinase inhibitors and antibody-drug conjugates, and mechanisms of resistance, in HER2-expressing breast cancers
… was observed with irreversible TKIs afatinib and neratinib plus T-DM1 or T-DXd in oestrogen receptor-negative (ER-)/HER2+ cell lines; and with almost all TKI/T-DXd combinations in ER+ cell lines. TKI/T-DXd synergy was observed in HER2+/ER+ BT474 3D spheroid models. In vivo work showed strong …
-
Exploration of the gut microbiome as a predictive factor for cancer treatment-induced gastrointestinal toxicity
… in diarrhoea stemming from the SM-TKI treatment neratinib, which causes high levels of diarrhoea. I found that, in a pre-clinical model, neratinib treatment does cause changes to microbial composition, however it was unclear if these changes were a key driver of diarrhoea development or simply a …
-
FUNCTIONAL VALIDATION OF NOVEL HER2 MUTANTS IN HORMONE RECEPTOR POSITIVE BREAST CANCER
… by using irreversible HER2 kinase, inhibitor neratinib. Lastly, we report that constitutive HER2 homodimerization via reduction-sensitive disulfide bridges is a more common mechanism of HER2 hyperactivation than previously appreciated, which may provide further insights into HER2 and receptor …
-
Subclonal Sociability: Interactions of PIK3CA and HER2 Mutant Cells in Breast Cancer
… that drugs targeting either HER2 mutant cells (Neratinib), or PIK3CA mutant cells (Alpelisib) could effectively inhibit the growth of the co-cultures.
-
PHENOTYPIC CHARACTERIZATION OF NOVEL HER2 MISSENSE MUTANTS AND INVESTIGATING THE ROLE OF INFLAMMATORY SIGNALING IN ER+ ADVANCED BREAST CANCER
… to the combination treatment of fulvestrant and neratinib, an irreversible tyrosine kinase inhibitor. In the second project, we focused on the inflammatory signaling in ER+ HER2mut breast cancer. We report the ERK-dependent upregulation of stimulator of interferon genes (STING) and the …
-
NOVEL HER2 MUTATIONS CONFER ENDOCRINE RESISTANCE IN ER+ HER2- BREAST CANCER
… the second-generation tyrosine kinase inhibitor neratinib.
-
Regulation of IRF5 activity in inflammatory diseases: novel kinases
… Chemical modifications of the lead compound Neratinib resulted in the identification and synthesis of analogs with comparable biochemical potency on MEKK3, improved selectivity on a small panel of pathway relevant kinases, with reduced IRF5-driven TNF activation in an IRF5- and MEKK3- …
-
Modeling HER2 Mutations in Colorectal Cancer using a HER2 Transgenic Mouse Model and Gastrointestinal Organoids
… sensitivity to a HER2-targeted therapeutic, neratinib, which further illustrates the impact of multiple oncogenic mutations on cell growth. Taken together, we illustrate the role of HER2 and co-occurring mutations on the intestinal epithelium as well as the effect of HER2 and KRAS …
-
The role of HER4 in relation to trastuzumab resistance and prognosis in HER2 positive breast cancer
… cleavage since γ-secretase inhibitor (GSi) and neratinib prevented the process when combined with trastuzumab treatment, correlating with an increased apoptosis and decreased cell viability. There was also increased nuclear HER4 expression in tumors from both BT474 xenografts and from patients …
-
Identification of tumour progression genes in a mouse model for non-small cell lung cancer
… mouse tumours with the pan-ErbB-family inhibitor Neratinib and the WNT-inhibitor LGK974. Single treatment with either inhibitor suppressed cell propagation, migration and invasion into Matrigel, whereas combined treatment had a stronger effect on both characteristics. A panel of KRas mutant human …
-
Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer
… margetuximab, T-DM1, T-DXd, lapatinib, neratinib, pyrotinib, gefitinib, and tucatinib, have been developed. Nonetheless, despite of their improved effectiveness, de novo and acquired resistance to current treatments are very common in BC patients; almost all develop resistance with these …
-
Συστηματική ανασκόπηση της ασφάλειας των νεότερων θεραπειών οι οποίες χρησιμοποιούνται στη θεραπεία του καρκίνου του πνεύμονα HER2+
… Τυροσινικής Κινάσης (Poziotinib, Pyrotinib, Neratinib, Afatinib, Tarloxotinib, Dacomitinib). Η συλλογή και ανάλυση των αποτελεσμάτων των κλινικών δοκιμών συμβάλλει καθοριστικά στην αποτελεσματική χρήση των καινοτόμων θεραπευτικών μεθόδων αλλά και στην παροχή ενός υψηλότερου επιπέδου …